Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028171 · ClinicalTrials.gov registry record · NA
Pharmacokinetics of Tacrolimus in Kidney Transplant Recipients: Once Daily Versus Twice Daily Dosing
A NA study, sponsored by National Center for Research Resources (NCRR).
- Completed
- Registry status
- NA
- Development phase
NCT00028171: Completed NA study, sponsored by National Center for Research Resources (NCRR).
NCT00028171 is a NA study that has completed, run by National Center for Research Resources (NCRR). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00028171, a NA study, has completed, sponsored by National Center for Research Resources (NCRR).
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
Tacrolimus is a medication given to transplant patients to help prevent rejection. The purpose of this study is to see if tacrolimus can be taken once a day instead of twice a day in kidney transplant patients. Transplant patients are required to take several medications to prevent rejection and to treat complications after their transplantation. Because of the complicated dosing schedule, it can be difficult for patients to follow their medication schedule. Taking fewer medications less frequently may help transplant patients to better manage their drug therapy. Tacrolimus is better absorbed in the body if it is taken in the morning than if it is taken in the evening. This suggests that tacrolimus can be taken once every morning instead of twice daily in order to produce appropriate drug exposure to prevent organ rejection without increased side effects.
Interventions
- DRUG Tacrolimus
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00028171 record still lists
NCT00028171 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Tacrolimus is the first listed.
NCT00028171 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00028171 about?
NCT00028171 is a clinical study titled "Pharmacokinetics of Tacrolimus in Kidney Transplant Recipients: Once Daily Versus Twice Daily Dosing". Tacrolimus is a medication given to transplant patients to help prevent rejection. The purpose of this study is to see if tacrolimus can be taken once a day instead of twice a day in kidney transplant patients. Transplant patients are required to take several medications to prevent rejection and to...
What is the current status of trial NCT00028171?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00028171?
The interventions under investigation include: Tacrolimus (DRUG).
Who is sponsoring clinical trial NCT00028171?
This trial is sponsored by National Center for Research Resources (NCRR), which has 94 total clinical trials registered on ClinicalTrials.gov.